An intranasal vaccine durably protects against SARS-CoV-2 variants in mice

Hassan, Ahmed O.; Shrihari, Swathi; Gorman, Matthew J.; Bai, Ying; Yaun, Dansu; Raju, Saravanan; Chen, Rita E.; Dmitriev, Igor; Kashentseva, Elena A.; Adams, Lucas J.; Mann, Colin; Davis-Gardner, Meredith E.; Suthar, Mehul S.; Shi, Pei Yong; Saphire, Erica Ollmann; Fremont, Daved H.; Curiel, David T.; Alter, Galit; Diamond, Michael S.

doi:10.1016/j.celrep.2021.109452

Cited by 112 publications

(80 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Neutralizing antibody titers were around two to eight times lower against Delta strain. Similar titer-fall has been previously described [33] . Nevertheless, all these results indicate antigenic similarities between both molecules, the RBDf and CRBDH6_HEKs, and support the fungal C1 expression system for the production of biotherapeutics.…”

Section: Discussionsupporting

confidence: 84%

A recombinant SARS-CoV-2 receptor-binding domain expressed in an engineered fungal strain of Thermothelomyces heterothallica induces a functional immune response in mice

Lazo

Bequet-Romero

Lemos

et al. 2022

Vaccine

View full text Add to dashboard Cite

Since the beginning of the COVID-19 pandemic, the development of effective vaccines against this pathogen has been a priority for the scientific community. Several strategies have been developed including vaccines based on recombinant viral protein fragments. The receptor-binding domain (RBD) in the S1 subunit of S protein has been considered one of the main targets of neutralizing antibodies. In this study we assess the potential of a vaccine formulation based on the recombinant RBD domain of SARS-CoV-2 expressed in the thermophilic filamentous fungal strain Thermothelomyces heterothallica and the hepatitis B virus (HBV) core protein. Functional humoral and cellular immune responses were detected in mice. To our knowledge, this is the first report on the immune evaluation of a biomedical product obtained in the fungal strain T. heterothallica. These results together with the intrinsic advantages of this expression platform support its use for the development of biotechnology products for medical purpose.

show abstract

Section: Discussionsupporting

confidence: 84%

A recombinant SARS-CoV-2 receptor-binding domain expressed in an engineered fungal strain of Thermothelomyces heterothallica induces a functional immune response in mice

Lazo

Bequet-Romero

Lemos

et al. 2022

Vaccine

View full text Add to dashboard Cite

show abstract

“…Notably, nasal delivery of IgM has been shown to offer broad protection from SARS-CoV-2 variants (53). Additionally, a single dose intranasal ChAd-SARS-CoV-2 S vaccine in mice induces durable and neutralizing IgG and IgA antibodies, which are effective in protecting against new variants of concern (54).…”

Section: Discussionmentioning

confidence: 99%

Intramuscular SARS-CoV-2 vaccines elicit varying degrees of plasma and salivary antibody responses as compared to natural infection

Nahass

Salomon-Shulman

Blacker

et al. 2021

Preprint

View full text Add to dashboard Cite

Vaccination induced antibody and T-cell immune responses are important for systemic protection from COVID-19. Because SARS-CoV-2 infects and is transmitted by oral-pharyngeal mucosa, we wished to test mucosal antibodies elicited by natural infection or intramuscular vaccine injection. In a non-randomized observational study, we measured antibodies against the SARS-CoV-2 RBD in plasma and saliva from convalescent or vaccinated individuals and tested their neutralizing potential using a replication competent rVSV-eGFP-SARS-CoV-2. We found IgG and IgA anti-RBD antibodies as well as neutralizing activity in convalescent plasma and saliva. Two doses of mRNA vaccination (BNT162b2 or mRNA-1273) induced high levels of IgG anti-RBD in saliva, a subset of whom also had IgA, and significant neutralizing activity. We detected anti-RBD IgG and IgA with significant neutralizing potential in the plasma of single dose Ad26.COV2.S vaccinated individuals, and we detected slight amounts of anti-RBD antibodies in matched saliva. The role of salivary antibodies in protection against SARS-CoV-2 infection is unknown and merits further investigation. This study was not designed to, nor did it study the full kinetics of the antibody response or protection from infection, nor did it address variants of SARS-CoV-2.

show abstract

“…Recent studies in mice, hamsters, and NHPs show that animals previously infected or vaccinated against lineage A SARS-CoV-2 (for example, the original Wuhan strain) [7] are protected against challenge with homologous as well as heterologous virus strains including the alpha (B.1.1.7), beta (B.1.351), gamma (B.1.1.28.1), and delta (B.1.617.2) VOCs [8][9][10][11][12][13][14]. In the NHP model, however, more viral breakthroughs were observed following beta VOC challenge as compared with homologous WA1/2020 challenge [12,15].…”

Section: Vaccine Cross-protection and Transmissionmentioning

confidence: 99%

Advances and gaps in SARS-CoV-2 infection models

et al. 2022

Self Cite

View full text Add to dashboard Cite

The global response to Coronavirus Disease 2019 (COVID-19) is now facing new challenges such as vaccine inequity and the emergence of SARS-CoV-2 variants of concern (VOCs). Preclinical models of disease, in particular animal models, are essential to investigate VOC pathogenesis, vaccine correlates of protection and postexposure therapies. Here, we provide an update from the World Health Organization (WHO) COVID-19 modeling expert group (WHO-COM) assembled by WHO, regarding advances in preclinical models. In particular, we discuss how animal model research is playing a key role to evaluate VOC virulence, transmission and immune escape, and how animal models are being refined to recapitulate COVID-19 demographic variables such as comorbidities and age.

show abstract

An intranasal vaccine durably protects against SARS-CoV-2 variants in mice

Cited by 112 publications

References 73 publications

A recombinant SARS-CoV-2 receptor-binding domain expressed in an engineered fungal strain of Thermothelomyces heterothallica induces a functional immune response in mice

A recombinant SARS-CoV-2 receptor-binding domain expressed in an engineered fungal strain of Thermothelomyces heterothallica induces a functional immune response in mice

Intramuscular SARS-CoV-2 vaccines elicit varying degrees of plasma and salivary antibody responses as compared to natural infection

Advances and gaps in SARS-CoV-2 infection models

Contact Info

Product

Resources

About